8-K: ZimVie Addresses Merger Lawsuits with Proxy Disclosures

ZimVie Inc. has filed supplemental disclosures to its merger proxy statement in response to stockholder litigation alleging material omissions, aiming to avoid delays in its acquisition by Zamboni Parent Inc.

Summary

• ZimVie Inc. (ZIMV) entered into a Merger Agreement on July 20, 2025, to be acquired by Zamboni Parent Inc. for $19.00 per share in cash.
• A definitive proxy statement was filed on September 2, 2025, in connection with the merger.
• Two lawsuits were filed in New York and one in Florida by purported stockholders, alleging the proxy statement omitted material information and asserting claims for negligent misrepresentation, concealment, and negligence.
• Attorneys representing several stockholders also sent demand letters with similar allegations.
• The lawsuits seek remedies including enjoining or rescinding the merger, awarding damages, and covering legal fees.
• ZimVie believes the allegations are without merit and no further disclosures are legally required.
• To avoid delaying the merger and minimize litigation costs, ZimVie voluntarily made supplemental disclosures to the proxy statement.
• These supplemental disclosures do not change the merger consideration or the timing of the Special Meeting, scheduled for October 10, 2025.
• The Board of Directors continues to unanimously recommend that stockholders vote FOR the merger proposals.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the ongoing stockholder litigation and allegations of material omissions, which introduce legal risk and uncertainty. While the company is proactively addressing these issues with supplemental disclosures and the Board still unanimously recommends the merger, the existence of lawsuits seeking to enjoin the transaction is a significant concern.

Positives

• ZimVie is proactively making supplemental disclosures to mitigate the risk of litigation delaying or adversely affecting the merger, demonstrating a commitment to closing the transaction.
• The Board of Directors continues to unanimously recommend the merger, indicating their confidence in the transaction's value for shareholders.
• Centerview's updated disclosure letter confirmed no fee-paying engagements with ARCHIMED or its affiliates since January 1, 2023, and no ownership of securities, suggesting a lack of conflicts of interest from the financial advisor.

Negatives

• Multiple stockholder lawsuits have been filed, alleging material omissions and misrepresentations in the proxy statement, which introduces legal risk and uncertainty to the merger process.
• The lawsuits seek significant remedies, including enjoining or rescinding the merger, which could prevent the transaction from closing or force a renegotiation.
• The company is incurring costs, risks, and uncertainties inherent in litigation, even if it believes the allegations are without merit.

Risks

• The proposed transaction may not be completed in a timely manner or at all.
• Failure to receive required approvals from the company's stockholders.
• Various conditions to the consummation of the proposed transaction may not be satisfied or waived.
• Possibility of competing offers or acquisition proposals for the company.
• Occurrence of any event, change, or circumstance that could lead to the termination of the definitive transaction agreement, potentially requiring the company to pay a termination fee.
• The announcement or pendency of the proposed transaction could negatively affect the company's ability to attract, motivate, or retain key executives and employees, and maintain relationships with customers, suppliers, and other business counterparties.
• The proposed transaction may divert management's attention from ongoing business operations.
• Risk of stockholder litigation in connection with the proposed transaction, including resulting expense or delay.

Future Outlook

The company anticipates the merger with Zamboni Parent Inc. will proceed, with the Special Meeting for stockholder approval scheduled for October 10, 2025. While the company believes the current litigation is without merit, it is making voluntary supplemental disclosures to mitigate the risk of delays. There is a possibility that additional similar complaints or demand letters may be filed. Certain executive officers may engage in discussions with ARCHIMED or its affiliates regarding future employment or equity participation post-merger.

Management Comments

• We believe that the allegations contained in the Litigation Matters are without merit and that no further disclosures are required to supplement the Proxy Statement under applicable laws.
• In order to avoid the risk of the Litigation Matters delaying or adversely affecting the Merger and to minimize the costs, risks and uncertainties inherent in litigation, and without admitting any liability or wrongdoing, we have determined to voluntarily make supplemental disclosures.
• Nothing in this Current Report on Form 8-K shall be deemed an admission of the legal necessity or materiality under applicable laws of any of the disclosures set forth herein. To the contrary, we specifically deny all allegations in the Litigation Matters and that any additional disclosure was or is required.
• These supplemental disclosures will not change the consideration to be paid to the Company stockholders in connection with the Merger or the timing of the special meeting.
• The Board continues to unanimously recommend that you vote FOR the proposals to be voted on at the Special Meeting.

Industry Context

Shareholder litigation challenging merger disclosures is a common occurrence in M&A transactions, particularly when the acquisition price is below certain valuation metrics or analyst targets. Companies often make supplemental disclosures, even without admitting fault, to expedite the merger process and avoid costly delays or injunctions. The valuation metrics and comparable transactions cited in the filing are standard for financial advisory opinions in the medical device and healthcare sectors, which frequently see consolidation.

Comparison to Industry Standards

• Selected Public Company Analysis: ZimVie's implied per share equity value range of $14.00 to $18.75, based on a median EV/2025E Adj. EBITDA of 11.0x, compares to the merger consideration of $19.00. Comparable companies included Align Technology (12.4x), DENTSPLY SIRONA (6.8x), Envista Holdings (9.3x), Henry Schein (11.0x), and Straumann Group (19.6x). The merger consideration is at the higher end of this implied range.
• Selected Precedent Transaction Analysis: ZimVie's implied per share equity value range of $17.00 to $21.25, based on a median TV/LTM Adj. EBITDA of 9.9x, encompasses the $19.00 merger consideration. Precedent transactions included Patterson Companies/Patient Square Capital (9.9x), Vantive/The Carlyle Group Inc. (8.8x), KaVo Treatment Unit & Instrument Business/Planmeca Oy (6.4x), Analogic Corporation/Altaris Capital Partners, LLC (11.3x), and Zest Dental Solutions/BC Partners (11.2x).
• Precedent Premia Paid Analysis: The implied price range of $10.50 to $14.00 per share, derived from applying a 25% to 65% premium to ZimVie's pre-announcement closing price of $8.44, is significantly lower than the $19.00 merger consideration. This suggests the merger consideration offers a substantial premium compared to historical averages for similar transactions.
• Analyst Price Target Analysis: Wall Street analyst price targets ranged from $9.00 to $16.00, with a median of $10.00. The $19.00 merger consideration is notably higher than these analyst targets, indicating a favorable outcome for shareholders compared to prior market expectations.

Legal Proceedings

• Robert Williams v. ZimVie Inc., et al. (N.Y. Sup. Ct., filed September 17, 2025): Alleges Proxy Statement omitted material information, negligent misrepresentation, concealment, and negligence.
• Richard McDaniels v. ZimVie Inc., et al. (N.Y. Sup. Ct., filed September 18, 2025): Alleges Proxy Statement omitted material information, negligent misrepresentation, concealment, and negligence.
• Martin Siegel v. Asar, et al. (Fla. Cir. Ct., filed September 17, 2025): Alleges Proxy Statement omitted material information, violation of New Jersey Uniform Securities Law (1997), negligent misrepresentation, concealment, and negligence.
• Demand letters from attorneys representing purported stockholders alleging similar insufficiencies in Proxy Statement disclosures.

Related Party Transactions

• Centerview provided an updated customary disclosure letter, which did not identify any fee-paying engagements with ARCHIMED or any affiliated investment funds or portfolio companies of ARCHIMED since January 1, 2023.
• Centerview's disclosure letter also did not identify any ownership of securities of the Company or ARCHIMED or any affiliated investment funds or portfolio companies of ARCHIMED.

Stakeholder Impact

• Shareholders: The merger consideration of $19.00 per share remains unchanged. However, the litigation introduces uncertainty regarding the merger's completion and potential delays. The Board continues to recommend the merger.
• Employees/Executive Officers: Certain executive officers may have discussions and enter into agreements with ARCHIMED or its affiliates regarding employment or equity participation post-merger, indicating potential changes or continuity for key personnel.
• Company: Faces legal costs and potential distraction from ongoing business operations due to the litigation, even if it believes the claims are without merit.

Next Steps

• Hold the Special Meeting of Company stockholders on October 10, 2025, to vote on the merger proposals.
• Potentially engage in discussions between executive officers and ARCHIMED or its affiliates regarding future employment or equity participation post-merger.
• Monitor for potential additional similar complaints or demand letters related to the merger.

Key Dates

Recommendation

The stock is currently subject to a definitive merger agreement at $19.00 per share. While the ongoing stockholder litigation introduces uncertainty and potential for delay, the company is proactively addressing the concerns with supplemental disclosures, and the Board unanimously continues to recommend the merger. The merger consideration of $19.00 per share is at the higher end or above various valuation metrics (public company analysis, analyst targets) and represents a significant premium over the pre-announcement trading price. An investor should 'hold' to await the outcome of the Special Meeting and the resolution of the litigation, as the current price likely reflects the merger consideration less a discount for the risk of non-completion. Selling now would lock in a lower price, while buying carries the risk of the merger failing or being delayed, but the Board's strong recommendation and the company's proactive steps suggest a reasonable probability of completion.

Keywords

Merger, Acquisition, SEC Filing, 8-K, Stockholder Litigation, Proxy Statement, ZimVie, Zamboni Parent, Corporate Governance, Financial Advisory, Valuation, Healthcare, Medical Devices